8/9/2016 - See case T-472/13.

8/9/2016 - The Commission welcomes the General Court's jugments which upheld the Commission's Lundbeck decision (cases T-472/13, T-460/13, T-467/13, T-469/13, T-470/13, T-471/13) and ruled for the first time that pharma pay-for-delay agreements breach EU antitrust rules. In such agreements an original pharmaceutical manufacturer pays generics producers to stay out of the market. The Commission's decision found that the Danish pharmaceutical company Lundbeck and four generics competitors had concluded agreements that harmed patients and health care systems. This allowed Lundbeck to keep the price of its blockbuster drug citalopram artificially high, in breach of Article 101 of the Treaty on the Functioning of the European Union. The decision imposed a fine of €93.8 million on Lundbeck and fines totalling €52.2 million on the four generics competitors, Generics UK, Arrow, Alpharma and Ranbaxy.

Fact sheet/Memo

8/9/2016 - The court of justice ruled on an appeal against a ruling in the carglass-cartel. The appellant argued against the initial findings of the court regarding an earlier appeal. The court dismissed the appeal in full.

28/04/2021. Today, the Commission welcomes the adoption of the first Single Market Programme by the co-legislators. With €4.2 billion over the period of 2021-2027, the Programme provides an integrated package to support and strengthen the governance of the Single Market, including for financial services. The COVID-19 pandemic has shown the importance of a well-functioning Single Market for the resilience of our economy. This Programme provides a dedicated budget to boost the Single Market.